Changes to LTBI Screening in New Diagnoses of HIV during the COVID-19 Pandemic

M Henderson1,2, S Ojinnaka2, L Garvey2, NE Mackie4, B Mora-Peris1,2
Imperial College London1, Imperial College Healthcare NHS Trust2

BACKGROUND
The British HIV Association recommends screening for latent tuberculosis infection (LTBI) using an interferon gamma release assay (IGRA) in all persons with HIV (PWH) from:

• Medium and high-risk tuberculosis incidence countries
• Low risk countries with additional tuberculosis risk factors (Table 1).

The COVID-19 pandemic caused significant disruption to HIV/TB services.

AIM
We aimed to compare the percentage of newly diagnosed PWH screened for LTBI, prior to and during the first wave of the COVID-19 pandemic.

METHODS

• Retrospective case note review of all new diagnoses of HIV attending a central London HIV service over a 2-year period.
• Data was collected ‘pre-COVID-19’ (01/03/2019 – 28/02/2020) and ‘during-COVID-19’ (01/03/2020 – 30/03/2021).
• Risk of TB was determined by Public Health England estimates of number and rate of TB cases by country and WHO region.
• PWH were risk categorised: medium and high-risk TB countries, and low risk countries with additional TB risk factors (Table 1).
• Those with active TB symptoms (chronic cough, fever, night sweats and/or weight loss) or previous TB were excluded from the analysis.
• Comparisons between time periods and risk-factor groups were appropriately undertaken using Chi-squared or Fisher’s exact tests.

AIM

• A decline in the number of new diagnoses of HIV was seen during the first wave of the COVID-19 pandemic without significant changes in LTBI screening patterns.
• Clinicians should be aware of the need to screen those with additional tuberculosis risk factors, regardless of geographical tuberculosis risk.

RESULTS

• 86 new diagnoses of HIV were identified: 53/86 (62%) ‘pre’ and 33/86 (38%) ‘during’ COVID-19.
• Median age was 36 years (range 17-72) and 67/86 (78%) were male.
• Absolute CD4 count was ≤ 200 cells/μL in 22/86 (26%) individuals.
• 34/86 (40%) were eligible for LTBI screening, of which 24/34 (71%) were screened over the two-year period, all using an IGRA. No statistically significant differences were seen in the number screened between time periods (Table 1).
• Overall, more patients who presented with a geographical tuberculosis risk were screened than those from low-risk groups with additional tuberculosis risk factors (78% vs. 43%; p value=0.16) (Table 1).
• Of those screened, 3/24 (12.5%) were positive, all from medium and high-risk countries.

Table 1. Number screened for LTBI based on risk category and year

<table>
<thead>
<tr>
<th>Risk Category</th>
<th>Total screened</th>
<th>Number screened in 2019-2020, n=17</th>
<th>Number screened in 2020-2021, n=7</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total eligible for screening, n=34</td>
<td>24/34 (71%)</td>
<td>17/23 (77%)</td>
<td>7/11 (63%)</td>
<td>0.54</td>
</tr>
<tr>
<td>Medium-high risk country, n=27</td>
<td>21/27 (78%)</td>
<td>14/17 (82%)</td>
<td>7/10 (70%)</td>
<td>0.64</td>
</tr>
<tr>
<td>Low risk country with additional TB risk factors, n=7</td>
<td>3/7 (43%)</td>
<td>3/6 (50%)</td>
<td>0/1 (0%)</td>
<td>1</td>
</tr>
</tbody>
</table>

*Additional TB risk factors include: PLWH with CD4+ cell counts <200 cells/mm³, recent exposure to a known TB case, Diabetes mellitus, Stage 4/5 chronic kidney disease, immunosuppressant agents, Travel to or periods of time spent in medium or high-incidence countries (>12 months), History of working in medical settings in countries with medium or high TB incidence, injecting drug use

CONCLUSIONS

• A decline in the number of new diagnoses of HIV was seen during the first wave of the COVID-19 pandemic without significant changes in LTBI screening patterns.
• Clinicians should be aware of the need to screen those with additional tuberculosis risk factors, regardless of geographical tuberculosis risk.